Navigation Links
Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
Date:11/11/2008

Study highlights:

- Researchers present promising results from dose-ranging study of new oral anti-coagulant in patients with acute coronary syndrome.

- Phase III trial slated to begin in December.

NEW ORLEANS, Nov. 11 /PRNewswire-USNewswire/ -- Researchers reported on a study of a new oral anti-clotting agent -- rivaroxaban -- designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.

"The goal of any early study is to find the right dose and the right way to give the drug, and we met that objective," said C. Michael Gibson, M.S., M.D., principal investigator, chief of clinical research at the Beth Israel Deaconess Medical Center and director of the Thrombolysis in Myocardial Infarction (TIMI) data coordinating center at Brigham and Women's Hospital, Boston, Mass. "We studied four different doses and both once-a-day and twice-a-day dosing schedules for this Factor Xa, (pronounced ten-A) inhibitor."

The Phase II, randomized, placebo-controlled study on 3,491 patients treated at 297 medical centers in 27 countries originally had safety as the primary endpoint, but its design also included efficacy endpoints, he said. The primary efficacy endpoint was a composite of death, heart attack, stroke and severe ischemia revascularization. The secondary endpoint was a composite of death, heart attack or stroke.

Earlier studies had shown the experimental drug rivaroxaban effective at keeping blood clots from forming in the veins during and after major orthopedic surgery. ATLAS ACS-TIMI 46 is the first test of the drug in the arteries -- which face higher pressures than the venous circulation -- and the first study of the drug in acute coronary syndrome, defined as a heart attack or unstable angina, said Gibson.

The drug was added to t
'/>"/>

SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
2. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
3. Derma Sciences Enrolls First Patient in DSC127 Phase II Study
4. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
5. Phase 2a Data for MEDI-528 Presented at CHEST 2008
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
8. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
9. Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
10. Teksouth Awarded $100,000 Defense Department Grant in First Phase of Medical Data Integration Project
11. Assessing the quality of phase I clinical trial abstracts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... New York, NY (PRWEB) November 24, 2014 ... performance, the progressive world of fitness technology will take center ... Living in Digital Times at the 2015 International ... 5:00pm in the Venetian, Level 2, Bellini 2004). The bond ... industry evolves into being less about devices and more about ...
(Date:11/24/2014)... Volpara Solutions announced today that it ... Annual Meeting of the Radiology Society of North ... 1752 – South Hall). Volpara Solutions will showcase ... of its innovative suite of quantitative breast imaging ... measurements of volumetric density, patient-specific dose, breast compression ...
(Date:11/24/2014)... 24, 2014 Olaparib functions as a ... and is one of the first PARP inhibitors. Sufferers ... some types of melanoma, and are often immune to ... gives their malignancies a exclusive weaknesses, as the tissues ... their DNA and allow them to proceed splitting. This ...
(Date:11/24/2014)... Raymond, Alberta (PRWEB) November 24, 2014 ... of people each day. They break up families, ... there is new hope for those that suffer,” ... “Ground-breaking scientific research is showing that our specialized ... , Hardy will appear on “Mind Over Matter”, ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 Gersowitz Libo ... that it has received national Tier recognition in the 2015 ... Achieving a tiered ranking signals a unique combination of quality ... very proud to receive this honor and especially grateful to ... this important honor and ranking possible,” said Jeff S. Korek, ...
Breaking Medicine News(10 mins):Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 2Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 3Health News:Next Wave Fitness Products Debut at FitnessTech Summit Living in Digital Times at the 2015 International CES 4Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2
... ER visits and additional imaging services , CHICAGO, ... quickly could cut by half the amount paid for hospital ... Clinical Congress of the American College of Surgeons. According to ... gallstones at the University of North Carolina in 2008, the ...
... onerous, futile medical interventions are ordered for these end-stage ... -- Many people see end-stage dementia as affecting only ... disease,s effects are far-reaching and eventually fatal. , ... not a terminal condition can have negative ...
... ... organization (PPO) plans in Albany, Essex, Rensselaer, Saratoga, Schenectady, Schoharie, Warren, and Washington counties, ... Medicare Choices individual PPO plans now serve Medicare-eligibles in 23 counties, while its group ... ...
... between brain and device , WEDNESDAY, Oct. 14 (HealthDay ... connections between prosthetic hands and the brain, potentially paving ... type, sense hot and cold, and touch others. , ... "would allow people to have a prosthetic that functions ...
... 14 The National Women,s Law Center,s (NWLC) groundbreaking ... Health Insurance Market Fails Women," first released in ... discriminates against women. Now, this ground-breaking research has resulted ... signed by Governor Schwarzenegger over the weekend -- that ...
... Oct. 14 The Guardian Life Insurance Company of America ... leading provider of employee and voluntary benefits for small and ... products and their sales force according to a study conducted ... that Guardian received "very good to excellent" ratings on all ...
Cached Medicine News:Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 2Health News:Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 3Health News:Families Need to Know When Dementia Becomes Terminal 2Health News:Families Need to Know When Dementia Becomes Terminal 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 2Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 3Health News:CDPHP Launches Individual Medicare Choices PPO Plan in the Capital Region 4Health News:Fine-Tuning Prosthetic Hands to Restore a Sense of Touch 2Health News:National Women's Law Center Challenges Insurance Industry Practices That Treat Being a Woman Like a 'Pre-Existing Condition' 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 2Health News:Guardian Recognized for Service, Products and Reputation by Independent Research Group 3
(Date:11/24/2014)... , Nov. 24, 2014  Surgical Theater, LLC, announced ... November 24 th opening of Europe,s ... Neurologico Nazionale "C. Besta." The SuRgical Planner (SRP) and ... at the event for their 3D navigation and augmented ... Joshua Bederson , Professor and Chair, Department of Neurosurgery ...
(Date:11/24/2014)... Nov. 24, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... , President and CEO of Inovio Pharmaceuticals, will be joined ... ring the Nasdaq Opening Bell tomorrow, Tuesday November 25, 2014, ... th listing on the Nasdaq Global Select Market.  ... said, "We are honored to ring the Nasdaq Opening Bell ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 2Inovio Pharmaceuticals to Ring Opening Bell Nov 25th on the Nasdaq Stock Market 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... budget pressures, countries around the world are making ... lure the biopharmaceutical research sector away from the ... Technology Partnership Practice. The study, commissioned ... (PhRMA), further found that while many countries are ...
...   Accuray Incorporated (Nasdaq: ARAY ), ... of Richard Pettingill, LFACHE as a member of the ... Richard Pettingill,s career as a healthcare executive ... variety of prominent organizations. Most recently, Pettingill, who is ...
Cached Medicine Technology:New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 2New Study Details Foreign Efforts To Lure Biopharmaceutical Companies 3Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 2Accuray Appoints Richard Pettingill, LFACHE to Board of Directors 3
... a rapid qualitative test for detection of ... serum samples. It can be used as ... infarction and can be useful to assess ... non-cardiac angina (e.g. gastric pain, strained chest ...
...
...
...
Medicine Products: